Your browser doesn't support javascript.
loading
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Weisberg, Ellen L; Puissant, Alexandre; Stone, Richard; Sattler, Martin; Buhrlage, Sara J; Yang, Jing; Manley, Paul W; Meng, Chengcheng; Buonopane, Michael; Daley, John F; Lazo, Suzan; Wright, Renee; Weinstock, David M; Christie, Amanda L; Stegmaier, Kimberly; Griffin, James D.
Afiliação
  • Weisberg EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Puissant A; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Stone R; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Sattler M; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Buhrlage SJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Yang J; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Manley PW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Meng C; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Buonopane M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Daley JF; Department of Biological Chemistry and Molecular Pharmacology, Boston, Massachusetts, USA.
  • Lazo S; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Wright R; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Weinstock DM; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Christie AL; Novartis Institutes of Biomedical Research, Basel, Switzerland.
  • Stegmaier K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Oncotarget ; 8(32): 52026-52044, 2017 Aug 08.
Article em En | MEDLINE | ID: mdl-28881711
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article